Alimentary/Metabolic
UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.
Roche's CT-388 shows promise in Phase II obesity trial but analysts question "commercial relevance" in a crowded market.
The company said amorphous rifaximin solid soluble dispersion did not meet the primary endpoint in two Phase III RED-C trials in the prevention of hepatic encephalopathy in patients with cirrhosis.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
The Danish firm is exiting the tricky development of diabetes cell therapy, allowing it to focus on its incretin therapy battle with Eli Lilly.
Two familiar heavyweights of the obesity field return for another match, while four smaller companies are tipped to bring their own blockbusters to market, new data from Evaluate Pharma show.
While the biotech sector is optimistic once more, the annual conference did not bring a bounce to many companies.
The company is currently well off the pace in obesity but believes some business development and a crossover with its Botox brand could help it compete.
CEOs of both the market leaders for weight-loss injections spoke at length during the J.P. Morgan Healthcare conference about the market potential for pills, which are gearing up to become the next frontier in the obesity treatment space.
Immunis thinks its secretome-based biologics could provide off-the-shelf therapies for metabolic conditions related to aging. Monotherapy or combination with GLP-1 agents is being considered.
Upcoming product launches from partnerships with J&J and Takeda could generate billions in royalties for the biotech, which now aims to build an in-house portfolio of next-generation oral obesity drugs and I&I therapies.
Amgen teases durability and convenience benefits for its weight management treatment MariTide but offers few hard numbers.
The firm's type 1 diabetes drug has been given the green light by the European Commission.
Another Phase III hit for Lilly’s Zepbound, the TOGETHER-PsA trial is the first to add an incretin therapy to anti-inflammatory biologic, potentially expanding its reach into another major comorbidity market.
The acquisition signals growing belief in the NLRP3 inhibitor class, where companies are increasingly pursuing cardiometabolic and obesity studies alongside neurodegenerative trials.
Ersodetug missed its Phase III primary endpoint in congenital hyperinsulinism but thinks building on data showing pharmacologic activity may offer a path to approval.
Following their 2022 cardiometabolic tie-up to target AMPK, Lilly is partnering with Nimbus on structure-based design for obesity in an undisclosed, “challenging” target.
The company announced encouraging interim data from two Phase I/IIa clinical trials testing two RNAi therapeutics for obesity, including in combination with tirzepatide.
With a starter dose price of $149 a month for self-payers, oral Wegovy will be available directly from Novo Nordisk and through telehealth providers and large pharmacy chains.
There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.